Gene Bridges granted Patents in Japan and Mexico for Recombineering Technology

Heidelberg, July 30, 2008 - Gene Bridges GmbH, the recombineering company, announced that it has been granted patents in Japan and in Mexico relating to the Company’s recombineering technology. The Japanese Patent (No. 4139561) was entitled "Novel DNA Cloning Method" while the Mexican Patent (No. 252928) was entitled “Methods and compositions for directed cloning and subcloning using homologous recombination”. Both patents broadly cover the major areas of Gene Bridges’ RED/ET Recombination technology. This is the same technology that is already covered by issued patents in the USA, EU, Korea and Israel.

Gary Stevens, CEO of Gene Bridges GmbH, commented:

‘Japan is a very important and growing market for us and this patent marks an important step in the international recognition of Red/ET while the Mexican patent strengthens our already strong position in North America.These important milestones in two new markets demonstrates that recombineering is the technology of choice in DNA engineering and is used worldwide in industry and academia.’ Gene Bridges is represented in Japan by the company Funakoshi.

Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome. Recombineering DNA using Red/ET has a number of advantages over conventional methods:

· Independent of restriction sites

· No size limits

· No unwanted mutations

· Rapid

Gene Bridges will be exhibiting at BIO Japan 2008 World Business Forum at Yokohama, Japan on October 15-17.

About Gene Bridges GmbH

Gene Bridges GmbH is a self-financed biotech company pioneering recombineering, the fast and precise method of engineering gene sequences. The Company was founded in 2000 as spin-off from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Gene Bridges commercialises its patented recombineering technology through services, commercial licenses and kits from its facilities in Heidelberg as well as through its distributors worldwide. Further information can be found by visiting www.genebridges.com.

Further Information:

Gary Stevens
CEO, Gene Bridges GmbH
t: +49 (0)6221-13708 10
e: Gary.Stevens@genebridges.com

College Hill Life Sciences
Douglas Pretsell
Account Director, Munich Bureau Chief
t : +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com